dr. kris on the eml4-alk translocation
Published 13 years ago • 590 plays • Length 0:55Download video MP4
Download video MP3
Similar videos
-
0:54
dr. li discusses the eml4-alk fusion gene
-
1:53
dr. kris on the crizotinib clinical trials
-
1:27
dr. kris on how the institutes in his study worked together
-
0:44
dr. mark kris discusses crizotinib for patients with alk-positive lung cancer
-
0:53
dr. kris discusses driver mutations test false negatives
-
1:14
dr. kris describes the use of genetic testing in lung cancer
-
1:38
dr. ravi salgia on eml4-alk in a cancer cell
-
3:18
the story of fusion genes: eml4-alk
-
4:56
what are treatment guidelines? with mark kris, md
-
6:02
shaw patterns of resistance in alk positive nsclc
-
3:34
alk-positive nsclc: the role of treatment selection and sequencing
-
0:31
dr. kris discusses available targeted therapies
-
26:24
the therapeutic implications of eml4/alk, ros-1 and other actionable biomarkers
-
22:21
the therapeutic implications of eml4/alk, ros-1 and other new biomarkers
-
1:47
alk rearrangements: what are they, and who has them?
-
1:04
dr. kris discusses egfr mutation testing
-
1:22
dr. crinò on crizotinib in alk nsclc
-
12:42
marileila varella garcia, phd: what is an alk gene and what does it mean for lung cancer patients?
-
9:33
second-line brigatinib for alk/ros1-rearranged nsclc
-
1:57
dr. shaw on sequencing strategies in alk-positive nsclc
-
8:37
alk inhibition in nsclc
-
1:07
dr. massarelli on first-line alk nsclc treatment